“joseph-schwartz” Archives

in
Entry Author Date Location
Ultragenyx Pharma Wins FDA’s First Drug Nod for Rare Metabolic Disorder 06/30/20 San Francisco
In an About-Face, FDA Approves Second Sarepta Muscular Dystrophy Drug 12/13/19 Boston
Astellas Bets On Gene Therapy With $3B Audentes Acquisition Offer 12/03/19 National
After AGTC Deal Flops, Biogen Bets $800M on Gene Therapy Rival Nightstar 03/04/19 Boston
With Its First Human Data, Solid Slips in Duchenne Gene Therapy Race 02/07/19 Boston
FDA Halts Clinical Test of Zafgen Diabetes Drug, Stock Price Tumbles 11/26/18 Boston
Data Starts Stretch Run for UniQure’s Upgraded Hemophilia Gene Therapy 11/15/18 Boston
Vertex Hums Along as AbbVie Snatches Up a Rival’s CF Drugs for $45M 10/25/18 Boston
FDA, Following EMA, Nixes Amicus’ Plans for Speedy OK of Pompe Drug 09/10/18 New York
Ultragenyx Makes Competing Bid for Gene Therapy Biotech Dimension Tx 09/18/17 San Francisco
Amicus’s Scioderm Deal Flops as Skin Drug Fails in Phase 3 09/13/17 New York
Ophthotech Eye Drug Fails Badly in Pivotal Test, Shares Crumble 12/12/16 New York
On Front Lines Of Price Dispute, Eye Doctors Wary of New Drug Data 11/01/16 National
Bio Execs Talk Patient Advocacy, Duchenne Approval at BioForward Panel 09/28/16 Wisconsin
Sarepta Prices $300K Duchenne Drug As FDA Rift Emerges Over Approval 09/19/16 Boston
At Duchenne Panel, Parents Plead With Experts, FDA Decision Looms 11/24/15 San Francisco
Biogen Drug Shows Early Promise in Slowing Alzheimer’s Decline 03/20/15 Boston
Amicus Counts on “Chaperone” Tech to Enhance Rare Disease Treatments 01/11/12 New York
Page 1 of 1